Drug Evaluation Committee Introduction of Single Sign-On (SSO) to the Current Status of Account Management in Clinical Trial-related IT Systems
Electronic Information Subcommittee
April 2024
While clinical trial-related operations are becoming increasingly IT-intensive, IDs and passwords need to be issued for as many systems as there are systems. In proportion to the number of systems, account management becomes more complicated and burdensome. The expected effects of using SSO are as follows.
- User accounts issued for each IT system can be centrally managed.
- It reduces the burden of account management for users and administrators of each system.
We have prepared a document introducing "Single Sign On (SSO)" in order to make the actual situation regarding SSO widely known.
This document introduces an example of an efficient means of account management in the utilization of clinical trial-related systems. We hope you will find it useful as a basic reference for those who are not in charge of IT departments, such as clinical trial personnel.
Japan Pharmaceutical Manufacturers Association, Committee on Drug Evaluation
Electronic Information Subcommittee 2023 Task Force 3
All members of the Account Management Study Team
-
As of December 2023Single Sign On: What is SSO?
A mechanism that enables multiple independent IT systems to be used through a single user authentication process.
Deliverables of the Drug Evaluation Committee Return to list of all deliverables